Guggenheim Raises Its Price Target on Arcutis Biotherapeutics, Inc. (ARQT) to $35 and Maintains a Buy Rating

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is among the 10 Fastest Growing NASDAQ Stocks to Buy.

Guggenheim Raises its Price Target on Arcutis Biotherapeutics, Inc. (ARQT) to $35 and Maintains a Buy Rating

On February 27, 2026, Guggenheim raised its price target on Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) to $35 from $34 and maintained a Buy rating. The firm said it remains “encouraged” by the trajectory of Zoryve and the company’s efforts to maximize its value through commercialization.

On February 26, 2026, TD Cowen raised its price target to $35 from $30 and kept a Buy rating, updating its model following Q4 results as management increased full-year 2026 guidance.

On February 25, 2026, Arcutis Biotherapeutics reported Q4 EPS of 13c, compared to the 9c consensus estimate. Q4 revenue was $129.5M versus consensus of $113.03M. President and Chief Executive Officer Frank Watanabe said that in 2025 the company delivered more than 90% year-over-year growth in net product revenue, reflecting demand for ZORYVE, execution across multiple product launches leveraging its differentiated profile, and early penetration into the topical steroid market. Watanabe added that the company is entering the next phase of growth with a solid cash position and resources to invest in ZORYVE’s continued growth and pipeline advancement.

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is a biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases.

While we acknowledge the potential of ARQT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ARQT and that has a 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 12 Best Tech Stocks that Beat Earnings Estimates and 40 Most Popular Stocks Among Hedge Funds Heading Into 2026

Disclosure: None. Follow Insider Monkey on Google News.